Rome wasn’t built in a day… But there is another lesser-known type of keystone, one that plays an equally critical role in supporting the most revolutionary technology the world’s ever seen… artificial intelligence. And without it, the entire AI industry would collapse.

You must read this new presentation from Porter Stansberry.

Richard S. Geary net worth and biography

Richard Geary Biography and Net Worth

EVP of Ionis Pharmaceuticals

Dr. Geary is the executive vice president and chief development officer at Ionis Pharmaceuticals. He is responsible for preclinical development, clinical development and clinical-stage manufacturing for Ionis’ antisense medicines. Since joining Ionis in 1995, Dr. Geary has been involved in discovery and development including the regulatory submission of more than 40 investigational new drug applications to U.S. and other regulatory agencies. In his position as head of development, Dr. Geary has led four successful antisense medicine late stage development programs through approvals in multiple jurisdictions.

During his tenure at Ionis, he has authored or co-authored 14 book chapters and more than 80 peer-reviewed manuscripts, which form a body of work that fully characterize the pharmacokinetics and metabolism of antisense medicines and the relationship of drug concentrations to activity and safety. Dr. Geary also serves on the Oligonucleotide Therapeutics Society (OTS) Board of Directors and co-leads the publication committee for Nucleic Acid Therapeutics.

Prior to joining Ionis, Dr. Geary was senior research scientist and group leader for the bioanalytical and preclinical pharmacokinetics group in the Applied Chemistry Department at Southwest Research Institute. Dr. Geary received his Ph.D. in Biopharmaceutics from the University of Texas, College of Pharmacy, Austin, Texas and his B.S. in Biology from Texas A&M University, College Station, Texas.

What is Richard S. Geary's net worth?: The estimated net worth of Richard S. Geary is at least $3.05 million as of August 28th, 2024. Dr. Geary owns 85,154 shares of Ionis Pharmaceuticals stock worth more than $3,049,365 as of December 3rd. This net worth evaluation does not reflect any other assets that Dr. Geary may own. Additionally, Dr. Geary receives a salary of $1,010,000.00 as EVP at Ionis Pharmaceuticals. Learn More about Richard S. Geary's net worth.
How old is Richard S. Geary?: Dr. Geary is currently 66 years old. There are 6 older executives and no younger executives at Ionis Pharmaceuticals. The oldest executive at Ionis Pharmaceuticals is Ms. B. Lynne Parshall Esq., J.D., Director, who is 70 years old. Learn More on Richard S. Geary's age.
What is Richard S. Geary's salary?: As the EVP of Ionis Pharmaceuticals, Inc., Dr. Geary earns $1,010,000.00 per year. There are 2 executives that earn more than Dr. Geary. The highest earning executive at Ionis Pharmaceuticals is Dr. Brett P. Monia Ph.D., Founder, CEO & Director, who commands a salary of $2,380,000.00 per year. Learn More on Richard S. Geary's salary.
How do I contact Richard S. Geary?: The corporate mailing address for Dr. Geary and other Ionis Pharmaceuticals executives is 2855 GAZELLE COURT, CARLSBAD CA, 92010. Ionis Pharmaceuticals can also be reached via phone at (760) 931-9200 and via email at [email protected]. Learn More on Richard S. Geary's contact information.
Has Richard S. Geary been buying or selling shares of Ionis Pharmaceuticals?: Richard S. Geary has not been actively trading shares of Ionis Pharmaceuticals over the course of the past ninety days. Most recently, Richard S. Geary sold 320 shares of the business's stock in a transaction on Wednesday, August 28th. The shares were sold at an average price of $49.16, for a transaction totalling $15,731.20. Following the completion of the sale, the executive vice president now directly owns 85,154 shares of the company's stock, valued at $4,186,170.64. Learn More on Richard S. Geary's trading history.
Who are Ionis Pharmaceuticals' active insiders?: Ionis Pharmaceuticals' insider roster includes Joseph Baroldi (EVP & Chief Business Officer), C. Bennett (EVP), Spencer Berthelsen (Director), Brian Birchler (EVP), Onaiza Cadoret-Manier (EVP), Breaux Castleman (Director), Stanley Crooke (Chairman), Allene Diaz (Director), Richard Geary (EVP), Elizabeth Hougen (CFO), Joseph Klein, III (Director), Brett Monia (CEO), Frederick Muto (Director), Patrick O'Neil (EVP), B. Parshall, Esq. (Director), Eugene Schneider (EVP), and Eric Swayze (EVP). Learn More on Ionis Pharmaceuticals' active insiders.
Are insiders buying or selling shares of Ionis Pharmaceuticals?: During the last year, insiders at the sold shares 25 times. They sold a total of 270,830 shares worth more than $13,480,539.63. The most recent insider tranaction occured on November, 12th when EVP Eric Swayze sold 1,194 shares worth more than $45,276.48. Insiders at Ionis Pharmaceuticals own 2.7% of the company. Learn More about insider trades at Ionis Pharmaceuticals.
Information on this page was last updated on 11/12/2024.

Richard S. Geary Insider Trading History at Ionis Pharmaceuticals

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
8/28/2024	Sell	320	$49.16	$15,731.20	85,154
8/5/2024	Sell	2,430	$48.00	$116,640.00	85,508
1/13/2021	Sell	141	$59.50	$8,389.50	30,306
11/24/2020	Sell	2,380	$50.83	$120,975.40	41,147
12/4/2019	Sell	10,000	$64.61	$646,100.00
12/2/2019	Sell	5,000	$65.06	$325,300.00	26,583
4/8/2019	Sell	46,240	$84.01	$3,884,622.40	45,442
2/13/2019	Sell	999	$60.00	$59,940.00	21,442
10/13/2017	Sell	8,268	$60.00	$496,080.00
1/16/2015	Sell	1,543	$67.96	$104,862.28
7/11/2013	Sell	9,000	$31.90	$287,100.00
7/9/2013	Sell	66,163	$30.03	$1,986,874.89
7/3/2013	Sell	5,000	$29.02	$145,100.00
6/25/2013	Sell	47,049	$26.20	$1,232,683.80

Richard S. Geary Buying and Selling Activity at Ionis Pharmaceuticals

Ionis Pharmaceuticals Company Overview

Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an antisense injection for the treatment of polyneuropathy caused by hereditary transthyretin amyloidosis in adults; and WAYLIVRA, an antisense medicine for treatment for familial chylomicronemia syndrome (FCS) and familial partial lipodystrophy. It also develops medicines for various indications that are in phase 3 study, including Eplontersen as a monthly self-administered subcutaneous injection to treat all types of ATTR; Olezarsen for patients with FCS and severe hypertriglyceridemia (SHTG); Donidalorsen for patients with hereditary angioedema; ION363 for patients with amyotrophic lateral sclerosis; Tofersen to inhibit the production of superoxide dismutase 1; Pelacarsen for patients with established cardiovascular disease and elevated lipoprotein(a); and Bepirovirsen to inhibit the production of viral proteins associated with hepatitis B virus. In addition, the company develops IONIS-FB-LRx to inhibit the production of complement factor B and the alternative complement pathway; and ION224 to reduce the production of diacylglycerol acyltransferase 2. It has a strategic collaboration with Biogen for the treatment of neurological disorders; and collaboration and license agreement with Metagenomi, Inc, AstraZeneca, Bayer AG, GlaxoSmithKline plc, Novartis, Roche, Swedish Orphan Biovitrum AB, and PTC Therapeutics. The company was incorporated in 1989 and is based in Carlsbad, California.

Today's Range

Now: $35.81

$35.20

$36.07

50 Day Range

MA: $37.95

$33.73

$41.10

2 Week Range

Now: $35.81

$33.33

$54.44

Volume

273,539 shs

Average Volume

1,326,234 shs

Market Capitalization

$5.65 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.35

This company will win the AI race

From Porter & Company | Ad

You must read this new presentation from Porter Stansberry.

Richard Geary Biography and Net Worth

What is Richard S. Geary's net worth?

How old is Richard S. Geary?

What is Richard S. Geary's salary?

How do I contact Richard S. Geary?

Has Richard S. Geary been buying or selling shares of Ionis Pharmaceuticals?

Who are Ionis Pharmaceuticals' active insiders?

Are insiders buying or selling shares of Ionis Pharmaceuticals?